Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance
Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance
复制标题
DOI：
10.1016/j.cyto.2018.09.019
复制
发表时间：
2019-01-01
期刊：
影响因子：
3.8
通讯作者：
Fallah, Soudabeh
中科院分区：
文献类型：
--
作者：
Fadaei, Reza;Moradi, Nariman;Fallah, Soudabeh
冠状动脉疾病（CAD）是全球范围内的主要死亡原因。动脉粥样硬化作为CAD的主要潜在机制与炎症和脂肪组织功能障碍有关。C1 q/TNF相关蛋白12（C1 q/TNF-related protein 12，CTRP 12）是新近发现的一种脂肪因子，是脂联素的副产物。CTRP 12具有抗炎和胰岛素增敏作用。据报道，这种脂肪因子的循环水平在2型糖尿病患者和多囊卵巢综合征患者中较低。为探讨冠心病患者血清CTRP 12水平及其与人体测量学和生化指标的关系，本研究采用酶联免疫吸附法（ELISA）检测了188例经冠状动脉造影证实的冠心病患者和70例正常对照者血清CTRP 12水平。采用ELISA试剂盒检测血清脂联素、TNF-α和IL-6水平。发现CAD患者中CTRP 12的血清水平（585.48 +/-201.67 pg/mL）低于对照组（814.86 +/-247.85 pg/mL; p < 0.001）。CTRP 12还显示与CAD风险独立相关（OR [CI] = 0.998 [0.996-0.999]; p = 0.019）。此外，在对照组中，它与HOMA-IR（r = 0.298; p = 0.012）和TNF-α（r = 0.269; p = 0.023）呈负相关，与脂联素（r = 0.344; p = 0.003）呈正相关。在CAD患者中，CTRP 12与BMI呈负相关，（r = 0.181，p = 0.013），HOMA-IR（r =-0.199; p = 0.006），TNF-α α（r =-0.259; p < 0.001）和IL-6（r =-320; p < 0.001），并与高密度脂蛋白胆固醇呈正相关（r = 0.342; p < 0.001）和脂联素（r = 0.398; p < 0.001）。本研究首次表明血清CTRP 12水平与CAD独立相关，并且CTRP 12与几种CAD危险因素相关。结果表明CTRP 12与动脉粥样硬化的致病机制，如炎症和高密度脂蛋白胆固醇代谢之间可能存在联系;然而，在这方面需要更多的研究。
Coronary artery disease (CAD) is the leading cause of death worldwide. Atherosclerosis as the main underlying mechanism of CAD is associated with inflammation and adipose tissue dysfunction. Clq/TNF-related proteinl2 (CTRP12) is a newly discovered adipokine which is a paralog of adiponectin. CTRP12 has anti-inflammatory and insulin sensitizing effects. Circulating levels of this adipokine have been reported to be lower in patients with type 2 diabetes and women with polycystic ovarian syndrome. The present study was undertaken for the first time to evaluate serum levels of CTRP12 in CAD patients and its association with anthropometric and biochemical parameters.Serum levels of CTRP12 were measured using ELISA kit in 188 CAD patients (angiography confirmed) and 70 controls. The serum levels of adiponectin, TNF-a and IL-6 were measured using ELISA kits. Serum levels of CTRP12 were found to be lower in CAD patients (585.48 +/- 201.67 pg/mL) than in the controls (814.86 +/- 247.85 pg/mL; p < 0.001). CTRP12 also showed an independent association with the risk of CAD (OR [CI] = 0.998 [0.996-0.999]; p = 0.019). Moreover, it showed an inverse correlation with HOMA-IR (r = 0.298; p = 0.012) and TNF-a (r = 0.269; p = 0.023) and a positive correlation with adiponectin (r = 0.344; p = 0.003) in the controls. In CAD patients, CTRP12 was inversely correlated with BMI (r = 0.181, p = 0.013), HOMA-IR (r =-0.199; p = 0.006), TNF-a alpha (r =-0.259; p < 0.001) and IL-6 (r =-320; p < 0.001) and a positive correlation with high density lipoprotein-cholesterol(r = 0.342; p < 0.001) and adiponectin (r = 0.398; p < 0.001).The present study showed for the first time that serum levels of CTRP12 are independently associated with CAD and that CTRP12 is associated with several CAD risk factors. The results suggest a possible link between CTRP12 and pathogenic mechanisms of atherosclerosis, such as inflammation and high density lipoprotein cholesterol metabolism; however, more study is required in this regard.